bioRxiv : the preprint server for biology

Key weaknesses in diverse patient-derived prostate cancer models identified using single-cell analysis and gene editing

Updated

Abstract

Essence

Single-cell multiomics plus CRISPR screening can reveal lineage-specific vulnerabilities in heterogeneous prostate cancer organoids.

Evidence

Patient-derived organoid resource and functional-genomics study profiled more than 190,000 cells across 22 CRPC and NEPC organoids and coupled the atlas to subtype-resolved pooled CRISPR-Cas9 screens.

Caveat

The target dependencies, including AHR in a hybrid stem-like/ASCL1 population, are derived from 3D human tumor models rather than clinical treatment outcomes.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Competing Interests. S.Z consults for Guidepoint and Gerson Lehram Group. C.L.S. is a cofounder of ORIC Pharmaceuticals and is a co-inventor of the prostate cancer drugs enzalutamide and apalutamide, covered by US patents 7,709,517; 8,183,274; 9,126,941; 8,445,507; 8,802,689; and 9,388,159 filed by the University of California. C.L.S. is on the scientific advisory boards for the following biotechnology companies: Beigene, Blueprint Medicines, Column Group, Foghorn, Housey Pharma, Nextech, PMV Pharma and ORIC.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free